NIH Blueprint Initiative: Tools for Germline Gene Editing in the Nervous System

The NIH Blueprint Initiative: Tools for Germline Gene Editing in the Nervous System is a forecasted federal funding opportunity issued by the National Institutes of Health under the U.S. Department of Health and Human Services. The opportunity is identified as RFA-DA-27-012 and is administered through the National Institute on Drug Abuse as part of the broader NIH Blueprint consortium that supports neuroscience research. The initiative is intended to strengthen and expand scientific tools and infrastructure for germline and somatic gene-editing research focused on the nervous system. NIH indicates that the funding opportunity is designed to support experimental systems that model key aspects of human brain anatomy, circuitry, cognition, behavior, and lifespan. The opportunity reflects NIH priorities related to advancing translational neuroscience research and improving the scientific community's ability to study neurological and neurodevelopmental disorders. The funding announcement emphasizes the development, optimization, validation, and application of transgenic and gene-editing approaches that can be used to better understand human brain function and disease. NIH specifically notes that the initiative builds on prior investments in marmoset gene-editing infrastructure and seeks to integrate New Approach Methodologies with other experimental models. The funding is intended to support comparative approaches involving human-derived methodologies and cross-species developmental studies. The agency highlights the importance of addressing complex neurological and behavioral disorders such as autism spectrum disorders, schizophrenia, and other developmental conditions that cannot yet be fully captured through currently available New Approach Methodologies. Applicants are expected to justify the use of their proposed models and demonstrate why the selected systems are necessary to study neuroanatomy, neural circuit function, cognition, behavior, lifespan phenotyping, or related human brain disease mechanisms. The opportunity is structured as a cooperative agreement funding mechanism. NIH expects to issue approximately four awards under the program with an estimated total program funding amount of $7,200,000. The published award ceiling is $1,200,000, while no award floor has been specified in the forecast notice. The anticipated project start date and estimated award date are both July 1, 2027. The funding opportunity falls under Assistance Listing 93.279, Drug Use and Addiction Research Programs. NIH states that the legal authorities governing the grant are 42 U.S.C. 241 and 284. The forecast notice does not identify a mandatory cost sharing or matching requirement, and the announcement explicitly states that no matching requirement applies to applicants. Eligibility for the opportunity is broad and includes state governments, county governments, city or township governments, special district governments, Native American tribal governments, Native American tribal organizations, public and private institutions of higher education, nonprofit organizations with and without 501(c)(3) status, small businesses, for-profit organizations other than small businesses, public housing authorities, independent school districts, and additional eligible entities described in the announcement. NIH also identifies eligible federal agencies, regional organizations, faith-based organizations, community-based organizations, U.S. territories or possessions, and non-domestic entities including foreign institutions as eligible applicants. The announcement therefore supports a nationwide and international eligibility scope with no state-specific geographic limitations identified in the forecast notice. Applicants should carefully justify the scientific necessity and relevance of their proposed model systems to NIH neuroscience priorities. The timeline published in the forecast notice indicates that the opportunity was forecasted on May 7, 2026, with an estimated posting date of August 10, 2026. The estimated application due date is October 12, 2026. Because the opportunity has not yet officially opened, applicants are currently in an early engagement phase and should begin preparing institutional registrations, scientific collaborations, and proposal development activities in advance of the estimated release date. The notice does not identify any required pre-application components such as letters of intent, concept papers, or pre-proposals. Similarly, the forecast notice does not yet provide detailed application instructions, evaluation criteria, or required submission forms, which are expected to become available upon official publication of the full funding announcement. The opportunity does not currently include detailed submission mechanics or review criteria in the forecast record. However, applicants can reasonably expect that NIH cooperative agreement applications will require scientific research plans, institutional assurances, budgets, personnel documentation, and compliance with NIH submission systems and policies. NIH encourages applicants to ensure that proposed projects are aligned with neuroscience research priorities and that proposed experimental systems are appropriate for the intended scientific questions. The primary contact listed for the opportunity is the NIDA GED Program Staff, and applicants are directed to communicate via email at NIDA_GED_Program@nida.nih.gov for additional information. The opportunity is currently classified as a forecasted discretionary federal grant opportunity and may be subject to revisions, additional guidance, or expanded eligibility details when the final notice of funding opportunity is officially released.

Clearly justify why proposed model systems are necessary for questions involving neuroanatomy circuit function cognition behavior lifespan phenotyping or human brain disease research; align proposals with NIH Blueprint neuroscience priorities and demonstrate relevance to complex neurological or developmental disorders.